Pharmaceuticals

Global Eylea Market Size and Forecast to 2029: Revenue, Growth, and Trends

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the eylea market from 2025–2034 with trusted insights from The Business Research Company

How Big Is The Eylea Market Size Today And What Will Its Value Be At The End Of 2029?

The eylea market has demonstrated significant expansion in recent years. It is projected to increase from $9.94 billion in 2024 to $10.51 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to several factors including the rising prevalence of diabetic macular edema (DME), its proven clinical efficacy and safety profile, the competitive environment with other anti-VEGF therapies, its approval for a range of retinal conditions, and a general shift towards intravitreal injections.

The eylea market is anticipated to experience robust growth over the next few years. It is expected to reach “$13.64 billion” by “2029”, at a compound annual growth rate (“CAGR”) of “6.7%”. The expansion during this forecast period can be attributed to several factors, including the emergence of new therapeutic indications, the introduction of biosimilar competition, heightened awareness and diagnostic rates, insights from real-world evidence and post-market studies, and patients’ preference for less frequent injections. Key trends foreseen in the forecast period encompass advancements in imaging technologies, the rise of telemedicine and remote monitoring, patient assistance programs, innovations in drug delivery technologies, specialized retinal imaging technologies, and ongoing clinical trials for new indications.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Which Key Drivers Are Powering Growth In The Eylea Market?

A rising occurrence of ocular diseases is anticipated to boost the Eylea market. Ocular diseases are eye conditions that hinder the proper functioning of the eye, negatively affecting vision and clarity. These conditions often present without symptoms until they reach an advanced stage. Eylea treats various ocular diseases, including wet age-related macular degeneration (AMD) and glaucoma, both of which damage the retina or macula, thus impacting vision. The medication works by blocking the protein responsible for developing new, weaker blood vessels and by slowing down swelling in the retina caused by blood vessel blockages. For instance, in October 2022, data from the BrightFocus Foundation, a US-based nonprofit organization focused on advancing research and support for macular degeneration and glaucoma, reported 80 million individuals globally with glaucoma, with a projected increase to over 111 million by 2040. Therefore, the expanding prevalence of ocular diseases is a key driver for the Eylea market.

Which Segment Categories Are Driving Maximum Growth In The Eylea Market?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

What Key Trends Are Driving Growth In The Eylea Market?

A prominent trend gaining traction in the eylea market revolves around research and development. A primary focus for major industry participants in eylea is the creation of innovative technical solutions. For instance, in August 2023, Regeneron Pharmaceuticals, Inc., a global biotechnology company based in the US dedicated to developing medicines for serious diseases, secured US FDA approval for Eylea HD (aflibercept) injection 8 mg. This approval is intended for patients experiencing wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The treatment’s administration schedule commences with an initial phase of every four weeks for the first three months across all mentioned indications, after which the intervals are modified to every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Who Are The Leading Companies Driving The Eylea Market?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Region Holds The Largest Share In The Eylea Market Today?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

Browse Through More Reports Similar to the Global Eylea Market 2025, By The Business Research Company

Iot In Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

Power Generators Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/power-generators-global-market-report

Ventricular Assist Device Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ventricular-assist-device-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795